Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Total Current Liabilities: HK$385 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Shenzhen Neptunus Interlong Bio-Technique Co Total Current Liabilities?

Shenzhen Neptunus Interlong Bio-Technique Co HKSE:08329 -5.71% Total Current Liabilities is HK$385 Mil as of Jun. 2026. The stock has 3 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Shenzhen Neptunus Interlong Bio-Technique Co's total current liabilities for the quarter that ended in Jun. 2026 was HK$385

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Shenzhen Neptunus Interlong Bio-Technique Co Total Current Liabilities Related Terms

Shenzhen Neptunus Interlong Bio-Technique Co Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Shenzhen Neptunus Interlong Bio-Technique Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Neptunus Interlong Bio-Technique Co Total Current Liabilities Chart

Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 410.39 463.38 403.17 362.28 361.61

Shenzhen Neptunus Interlong Bio-Technique Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 355.43 362.28 329.66 361.61 384.83

Shenzhen Neptunus Interlong Bio-Technique Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Shenzhen Neptunus Interlong Bio-Technique Co's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=234.03350479025+78.257692450792
+Other Current Liabilities+Current Deferred Liabilities
=34.487025965383+14.829320921846
=362

Shenzhen Neptunus Interlong Bio-Technique Co's Total Current Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=202.44124829782+109.05527751496
+Other Current Liabilities+Current Deferred Liabilities
=61.531904390308+11.80456549356
=385

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of HK$385 Mil mean?
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a Total Current Liabilities of HK$385 Mil as of Jun. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Shenzhen Neptunus Interlong Bio-Technique Co and its competitors.
Is Shenzhen Neptunus Interlong Bio-Technique Co's Total Current Liabilities too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current Total Current Liabilities is HK$385 Mil.
How does Shenzhen Neptunus Interlong Bio-Technique Co's Total Current Liabilities compare to ZTS?
Shenzhen Neptunus Interlong Bio-Technique Co's Total Current Liabilities of HK$385 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. Shenzhen Neptunus Interlong Bio-Technique Co's current Total Current Liabilities is HK$385 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.10 — trading 29.3% below its estimated fair value. The current Total Current Liabilities is HK$385 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current Total Current Liabilities is HK$385 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Address 979 King’s Road, 43rd Floor, One Taikoo Place, Quarry Bay, Hong Kong, HKG
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.